Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Cefto-Reallife Study: Real World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort

Carmen Hidalgo-Tenorio
* ORCID logo ,
Ines Pitto Robles
ORCID logo ,
Daniel Arnes Garcia
,
F Javier Membrill De Novales
ORCID logo ,
Laura Morata
ORCID logo ,
Rosario Menendez
,
Olga Bravo De Pablo
,
Vicente Abril Lopez de Medran
,
Miguel Salavert Lleti
ORCID logo ,
Pilar Vizcarra
ORCID logo ,
Jaime Lora Tamayo
,
Ana Arnaiz Garcia
ORCID logo ,
Leonor Moreno Nuñez
,
Mar Masia
,
Maria pilar Ruiz Seco
ORCID logo ,
Svetlana Sadyrbaeva Dolgova
ORCID logo
Version 1 : Received: 20 June 2023 / Approved: 21 June 2023 / Online: 21 June 2023 (04:10:08 CEST)

A peer-reviewed article of this Preprint also exists.

Hidalgo-Tenorio, C.; Pitto-Robles, I.; Arnés García, D.; de Novales, F.J.M.; Morata, L.; Mendez, R.; de Pablo, O.B.; López de Medrano, V.A.; Lleti, M.S.; Vizcarra, P.; Lora-Tamayo, J.; Arnáiz García, A.; Núñez, L.M.; Masiá, M.; Seco, M.P.R.; Sadyrbaeva-Dolgova, S. Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort. Antibiotics 2023, 12, 1218. Hidalgo-Tenorio, C.; Pitto-Robles, I.; Arnés García, D.; de Novales, F.J.M.; Morata, L.; Mendez, R.; de Pablo, O.B.; López de Medrano, V.A.; Lleti, M.S.; Vizcarra, P.; Lora-Tamayo, J.; Arnáiz García, A.; Núñez, L.M.; Masiá, M.; Seco, M.P.R.; Sadyrbaeva-Dolgova, S. Cefto Real-Life Study: Real-World Data on the Use of Ceftobiprole in a Multicenter Spanish Cohort. Antibiotics 2023, 12, 1218.

Abstract

Background: Ceftobiprole is a fifth-generation cephalosporin that has been approved in Europe solely for the treatment of community-acquired and nosocomial pneumonia. The objective was to analyze the use of ceftobiprole medocaril (Cefto-M) in Spanish clinical practice in patients with infection in hospital or outpatient parenteral antimicrobial therapy (OPAT). Methods: This retrospective, observational, multicenter study included patients treated from September 1, 2021 to December 31, 2022. Results: 249 individuals were enrolled, aged 66.6±15.4 years, 59.4% male, with Charlson index of 4 (IQR 2-6); 13.7% had COVID-19, and 4.8% were in intensive care unit (ICU). The most frequent type of infection was respiratory (55.8%), followed by skin and soft tissue infection (21.7%). Cefto-M was administered to 67.9% as empirical treatment, being in monotherapy for 7 days (5-10) in 53.8% of cases. The infection-related mortality was 11.2%.The highest mortality rates were for ventilator-associated pneumonia [40%], and infections due to methicillin-resistant S. aureus (20.8%) and Pseudomonas aeruginosa (16.1%). Mortality-related factors were age (OR: 1.1, 95%CI [1.04-1.16]), ICU admission (OR:42.02, 95%CI[4.49-393.4]), and sepsis/septic shock (OR:2.94, 95%CI [1.01-8.54]).Conclusions: In real life, Cefto-M is a safe antibiotic, with only half of prescriptions in respiratory infections, mainly administered as rescue therapy in pluripathological patients with severe infectious diseases.

Keywords

Ceftobiprole; sepsis; older; Real-World Data; OPAT

Subject

Medicine and Pharmacology, Medicine and Pharmacology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.